CannPal is a global leader in the development of innovative therapeutic products for pets. They provide veterinarians and pet owners with clinically validated and standardised therapeutics that are derived from cannabinoids, offering a safe and natural way to treat animals. CannPal is focused on developing products containing CBD, THC, and other active ingredients for registration as veterinary medicines and nutraceuticals.

Their range of products aims to address issues such as pain, inflammation, mood, and dermatological skin conditions in pets. As a subsidiary of AusCann Group Holdings, CannPal is dedicated to meeting the unmet needs of both humans and animals through the development and commercialisation of cannabinoid-derived therapeutic products. With a mission to treat pets in a safe and ethical way, CannPal envisions becoming a global leader in therapeutic products for companion animals